Safety and effectiveness of intravenous abatacept for polyarticular-course juvenile idiopathic arthritis: An all-case postmarketing surveillance study
An erratum to this article was published (Pediatr Rheumatol Online J, 12 Mar 2025 ↗)
Authors' conclusion
Abatacept is effective in polyarticular-course JIA, particularly in RF-positive patients, and in restoring a child's growth. Additionally, the incidence of ADRs is similar to that observed in the clinical trial.
Study context
- Population
- Japanese pediatric patients with refractory polyarticular-course juvenile idiopathic arthritis (JIA), February 2018 to August 202014.6% males, 85.4% females
- Participants
- 82 patients
- Outcome
- Real-world safety and effectiveness of abatacept
- Follow-up
- 52 weeks
Methodological detailsall-case, real-world, 52-week follow-up
- All-case
- Real-world
- 52-week follow-up
Main finding
As reported in the abstract
Incidence of adverse drug reactions
22.0%
Incidence of serious adverse drug reactions
2.4%
JADAS-27 low disease activity or less achieved during the study period
64.7%
Further findings
JADAS-27 scores in rheumatoid factor (RF)-positive polyarticular JIA, baseline vs 24 or 52 weeks
- Significant difference between baseline and 24 or 52 weeks
Height and weight standard deviation scores (SDS)
- Tended to improve during abatacept treatment
Safety
Adverse drug reactions (ADRs) · 52-week follow-up
- Incidence of ADRs
- 22.0%
Serious ADRs · 52-week follow-up
- Incidence of serious ADRs
- 2.4%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →